Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-04-17
2010-10-26
Chong, Yong S (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07820706
ABSTRACT:
A method of inducing ovulation in a female suffering from anovulatory infertility which comprises administering to said female two or more daily doses of at least one aromatase inhibitor. A method for augmenting ovulation in an ovulating female suffering from unexplained infertility or another type of ovulatory infertility which comprises administering to said female two or more daily doses of at least one aromatase inhibitor early in one or more menstrual cycles. A method of substantially reducing dosage levels of follicle stimulating hormone (FSH) for administration to a female undergoing infertility treatment which comprises administering a combination of two or more daily doses of at least one aromatase inhibitor (AI) with a plurality of daily doses of follicle stimulating hormone (FSH). A method of increasing response to a follicle stimulating hormone from a female who is a poor responder to follicle stimulation, which comprises administering a combination of two or more daily doses or at least one aromatase inhibitor (AI) with a plurality of daily doses of follicle stimulating hormone (FSH). Also disclosed are related pharmaceutical preparations and uses.
REFERENCES:
patent: 4845227 (1989-07-01), Hirsch et al.
patent: 6953774 (2005-10-01), Palmer et al.
patent: 7078236 (2006-07-01), Palmer et al.
patent: 43 300 237 (1995-03-01), None
patent: 196 22 457 (1997-11-01), None
Dowsett (“Aromatase Inhibitors come of age” Annals of Oncology, 8, 1997, 631-632).
“The Ovulatory Cycle and Drug Therapy-Letrozole Protocol”, Internet, ′Online!, Feb. 2001, Retrieved from the Internet: URL:http://www.babymakers.com/theovulatiorycycleanddrugtherapy.html, retrieved on Jul. 10, 2002.
Mohamed F. M. Mitwally et al, “Use of an Aromatase Inhibitor for Induction of Ovulation in Patients with an Inadequate Response to Clomiphene Citrate”, Fertility and Sterility, vol. 75, No. 2, Feb. 2001, pp. 305-309.
Mohamed F. Mitwally et al, “Aromatase Inhibition: A Novel Method of Ovulation Induction in Women with Polycyctic Ovary Syndrome”, Reproductive Technologies, vol. 10, No. 5, 2000, pp. 244-247.
Afonso et al., “Effects of the Aromatase Inhibitor Fadrozole on Plasma Sex Steroid Secretion and Ovulation Rate in Female Coho Salmon, Oncorhynchus kisutch, Close to Final Maturation”, General and Comparative Endocrinology, 113:221-229 (1999).
Sioufi et al., Biopharm. & Drug Disposition, 189:779-789 (1997).
Mitwally et al., The Aromatase Inhibitor, Letrozole: a Promising Alternative for Clomiphene Citrate for Induction of Ovulation. [Abstract No. O-091] In: Program and abstracts of The 56th Annual Meeting of the American Society for Reproductive Medicine (ASRM), Oct. 2000, San Diego, CA, USA.
Mitwally et al., The Aromatase Inhibitor, Letrozole, Decreases FSH Dose Required for Ovarian Superovulation. CFAS meeting: Newfoundland, Canada, Sep. 2000.
Mitwally et al., Aromatase Inhibition Decreases FSH Dose Needed During Controlled Ovarian Hyperstimulation: A Controlled Prospective trial. Meeting of the Society for Gynecologic Investigation, Mar. 2001, Toronto, Canada. Abstract published in J. Soc. Gynecol. Invest. 8 2001; p. 85A.
Mitwally et al., Aromatase Inhibition Improves Ovarian Response to FSH: A Potential Option for Low Responders During Ovarian Stimulation. The 48th meeting of the Pacific Coast Fertility Society Meeting, Rancho Las Palmas Resort and Spa, CA, USA. Apr. 2001.
Mitwally et al., The Use of an Aromatase Inhibitor for Induction of Ovulation in Cases of Clomiphene Citrate Failure, Hum. Reprod., 15:71-72 (2000).
Mitwally et al., Aromatase Inhibition Improves Ovarian Response to Follicle Stimulating Hormone in Poor Responders, Fertil. Steril., 77:776-780 (2002).
Mitwally et al., Aromatase Inhibition for Ovarian Stimulation: Future Avenues for Infertility Management, Curr. Opin. Obster. Gynecol., 14:255-263 (2002).
Mitwally et al., Aromatase Inhibition Improves Response to Conrolled Ovarian Hyperstimulation without the Antiestrogenic Effects of Clomiphene Citrate, ESHRE meeting: Lausanne, Switzerland, Jul. 2001.
Feutrie et al., Aromatase Inhibitors, Bull. Cancer, 86(10):821-827 (1999).
Coombes et al., Aromatase Inhibitors and Their Use in the Sequential Setting, Endocrine-Related Cancer, 6:259-263 (1999).
Dowsett et al., Anastrozole—A New Generation in Aromatase Inhibition: Clinical Pharmacology, Oncology, 54(Suppl 2):11-14 (1997).
Lipton et al., Letrozole: A Phase I Study of a New Potent Oral Aromatase Inhibitor of Breast Cancer, Cancer, 75(8):2132-2138 (1995).
Dowsett et al., Vorozole Results in Greater Oestrogen Suppression than Formestane in Postmenopausal Women and When Added to Goserelin in Premonopausal Women with Advanced Breast Cancer, Breast Cancer Research and Treatment, 56:25-34 (1999).
Dowsett, “Biological Background to Aromatase Inhibition,”The Breast, vol. 5, pp. 196-201 (1996).
Feutrie, “Aromatase Inhibitors,”Bulletin du Cancer, vol. 86, No. 10, pp. 821-827 (1990).
Marty et al., “ALS, a New Potent, Selective Aromatase Inhibitor Superior to Aminoglutethimide (AG) in Postmenopausal Women With Advanced Breast Cancer Previously Treated With Antioestrogens,”Proc Am Soc Clim Oncol, vol. 16, pp. 156 (1997).
Mitwally et al., “Aromatase Inhibition Decreases FSH Dose Needed During Controlled Ovarian Hyperstimulation: A Controlled Prospective Trial,” Meeting of the Society for Gynecologic Investigation, Abstract published inJ. Soc. Gynecol. Invest., vol. 8, pp. 85A (2001).
Mitwally et al., “Aromatase Inhibition Improves Ovarian Response to FSH: A Potential Option for Low Responders During Ovarian Stimulation,” The 48thMeeting of the Pacific Coast Fertility Society Meeting, Rancho Las Palmas Resort and Spa, (2001).
Mitwally et al., “Aromatase Inhibition: A Novel Method of Ovulation Induction in Women With Polycystic Ovarian Syndrome,”Reprod Technol, vol. 10, No. 5, pp. 244-247 (2001).
Mitwally et al., “The Aromatase Inhibitor, Letrozole: a Promising Alternative for Clomiphene Citrate for Induction of Ovulation, ” Program and Abstracts of the 56thAnnual Meeting of the American Society for Reproductive Medicine (ASRM), Oct. 2000, San Diego.
Mitwally et al., “The Use of an Aromatase Inhibitor for Induction of Ovulation in Cases of CLomiphene Citrate Failure,”Hum. Reprod., vol. 16, pp. 71-72 (2000).
The Ovulatory Cycle and Drug Therapy-Letrozole Protocol: Internet “Online Feb. 2001”; http://www.baby-makers.com/theovulatorycycleanddrugtherapy.html.
Adashi, “Clomiphene Citrate: Mechanism(s) and site(s) of Action—a Hypothesis Revisited,”Fertil Steril, vol. 42, No. 3, pp. 331-344 (1984).
Akhtar et al., “Mechanistic Studies on Aromatase and Related C-C Bond Cleaving P-450 Enzymes,”J. Steroid Biochem Mol Biol, vol. 44, pp. 375-387 (1993).
Archer et al., “Effects of Clomiphene Citrate on Episodic Luteinizing Hormone Secretion Throughout the Menstrual Cycle,”Am J. Obstet Gynecol, vol. 161, No. 3, pp. 581-589 (1989).
Basir et al., “Morphometric Analysis of Peri-Implantation Endometrium in Patients Having Excessively High Oestradiol Concentrations After Ovarian Stimulation,”Hum. Reprod., vol. 16, No. 3, pp. 435-440 (2001).
Bateman et al., “Exogenous Estrogen Therapy for Treatment of Clomiphene Citrate—Induced Cervical Mucus Abnormalities: Is It Effective?”Fertil Steril, vol. 54, pp. 577-579 (1990).
Ben-Ami et al., “Exogenous Estrogen Therapy Concurrent with Clomiphene Citrate—Lack of Effect on Serum Sex Hormone Levels and Endometrial Thickness,”Gynecol Obstet Invest, vol. 37, No. 3, pp. 180-182 (1994)/.
Cole et al., “Mechanism and Inhibition of Cytochrome P-450 Aromatase,”J. Med. Chem., vol. 33, pp. 2933-2944 (1990).
Coombes et al., “4-Hydroxyandrostenedione Treatment of Postmenopausal Patients with Advanced Breast Cancer,”The Lancet 2, pp. 1237-1239 (1984).
Dickey et
Casper Robert F.
Mitwally Mohamed F. M.
Ares Trading S.A.
Chong Yong S
Marshall & Gerstein & Borun LLP
LandOfFree
Multiple dose aromatase inhibitor for treating infertility does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multiple dose aromatase inhibitor for treating infertility, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multiple dose aromatase inhibitor for treating infertility will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200505